Riskpilot← Back to searchSign inGet full accessBioconcept AB
ABActiveOrg 5566673702Erik Dahlbergsallén 15Activities of agents involved in the wholesale of food, beverages and tobacco · NACE 4617Est. 20041-4 employees
Revenue 2024
SEK 13,3M
+67% vs 2023
EBITDA margin
11.1%
+265% vs 2023
Equity ratio
63.9%
Financial strength
Net profit 2024
SEK 1,3M
+239% vs 2023
| Revenue | SEK 13,3M | +67% |
| EBITDA | SEK 1,5M | +265% |
| Net profit | SEK 1,3M | +239% |
| Total assets | SEK 5,1M | +44% |
| Equity | SEK 3,2M | +68% |
| Employees | — | — |
Legal name
Bioconcept AB
Org number
5566673702
Legal form
Aktiebolag
NACE code
4617 · Activities of agents involved in the wholesale of food, beverages and tobacco
Founded
30 september 2004
Share capital
SEK 461 539
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Nordlander, Per Richard Anthony
Company purpose
Bolaget skall bedriva inköp, förädling och försäljning av livsmedel och naturläkemedel samt förmedling av immateriella rättigheter inom detta område ävensom idka därmed förenlig verksamhet.
Address
Erik Dahlbergsallén 15
Email
per@bioconcept.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 4 735 | 3 945 | 19 537 | 7 976 | 7 694 | 7 975 | 13 299 |
| Staff expenses | — | — | — | — | — | — | — | −1 114 | −1 259 | −1 444 |
| EBITDA | −14 | −161 | 298 | −2 000 | −2 434 | 2 824 | −819 | 430 | −888 | 1 470 |
| Depreciation & amort. | −70 | −0 | −0 | −0 | −44 | −44 | −44 | −44 | −44 | −115 |
| EBIT | −84 | −161 | 298 | −2 000 | −2 478 | 2 780 | −863 | 386 | −932 | 1 355 |
| Net financials | −19 | −18 | −8 | −9 | 12 | −851 | −16 | −141 | −12 | −42 |
| Profit before tax | −102 | −179 | 290 | −2 009 | −2 466 | 1 929 | −870 | 245 | −944 | 1 313 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — |
| Net profit | −102 | −179 | 290 | −2 009 | −2 466 | 1 929 | −870 | 245 | −944 | 1 313 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 396 | 684 | 7 196 | 4 422 | 2 016 | 3 995 | 4 680 | 3 681 | 3 525 | 5 059 |
| Equity | 54 | 75 | 6 038 | 4 027 | 1 561 | 3 490 | 2 620 | 2 865 | 1 921 | 3 234 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 294 | 98 |
| Short-term debt | 342 | 609 | 1 160 | 394 | 455 | 505 | 2 060 | 816 | 1 311 | 1 727 |
| Total debt | 342 | 609 | 1 160 | 394 | 455 | 505 | 2 060 | 816 | 1 605 | 1 826 |
EBITDA margin
11.1%
This company
15.8%
Market median
-30% vs market
20152024
Equity ratio
63.9%
This company
38.2%
Market median
+67% vs market
20152024
Return on equity
40.6%
This company
18.4%
Market median
+121% vs market
20152024
Net profit margin
9.9%
This company
8.1%
Market median
+22% vs market
20152024
Asset turnover
2.63×
This company
1.12×
Market median
+135% vs market
20152024
Debt / equity
0.56×
This company
0.62×
Market median
+10% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DC Audit | Audit | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bioconcept AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Daniel Chamaly | Audit | 0 companies |
| Carl Göran Läckgren | Deputy Board Member | 0 companies |
| Carl Johan Öhlin | Board of Directors | 0 companies |
| Rolf Allan Classon | Board of Directors | 0 companies |
| Per Erik Jonas Dahlquist | Board of Directors | 0 companies |
| Carl Anders Magnus Löfgren | Board of Directors | 0 companies |
| Per Richard Anthony Nordlander | Board of Directors | 0 companies |
| Bengt Christer Fellström | Chairman | 0 companies |